Compare Eli Lilly And Co (LLY) vs MakeMyTrip Ltd (MMYT) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

MakeMyTrip (MMYT) trades at $53.22, down 2.56% on the day, with a bullish technical signal and strong analyst support. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $0.25 exceeding expectations. Revenue for 2025 reached $978.34 million, though 2026 projections show a potential decline in net profit margin to 4.96%. Cash flow from operations remains healthy at $185.29 million, but a significant increase in liabilities is forecasted for 2026.

The outlook for MMYT is positive based on consistent earnings outperformance and a dominant market position in Indian online travel. Key risks include rising debt levels and travel demand volatility. With 72.73% of analysts rating it a Buy, the stock presents a growth opportunity, but investors must monitor execution against heightened financial leverage in the coming year.